3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
24
Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Endometrial Stromal Tumors
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
4
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
tivozanib
1
pembrolizumab
1
olaparib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
Secretin
1
STX-478
1
Radiotherapy
1
Pharmaceutical Preparations
1
Paclitaxel
1
Nivolumab
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
Carboplatin
1
CA-19-9 Antigen
1
Anastrozole
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hereditary Sensory and Autonomic Neuropathies
×
exemestane
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled